The CD13 test is a diagnostic laboratory evaluation used in hematopathology to detect the expression of the CD100/CD13 surface protein, also known as Aminopeptidase N. Naturally expressed on mature and immature myeloid cells, CD13 serves as an essential marker for lineage identification.
Conducted using flow cytometry or immunohistochemistry on blood or bone marrow samples, the test helps pathologists differentiate myeloid lineage leukemias from lymphoid malignancies. It is particularly vital for diagnosing Acute Myeloid Leukemia (AML) and identifying myeloid differentiation in acute leukemias. Ultimately, detecting CD13 assists clinicians in precise cancer subtyping, determining prognosis, and planning targeted therapeutic strategies.

The CD14 test is a diagnostic evaluation in hematopathology used to detect the CD14 cell-surface protein, a key co-receptor for bacterial lipopolysaccharide (LPS). Expressed heavily on monocytes and macrophages, CD14 serves as a primary marker for identifying monocytic cell lineages.
Conducted via flow cytometry on peripheral blood or bone marrow samples, this test helps clinicians distinguish monocytic leukemias from other myeloid and lymphoid malignancies. It is particularly valuable for diagnosing Acute Monocytic Leukemia (AML-M5) and Chronic Myelomonocytic Leukemia (CMML). Detecting CD14 expression provides essential insights for accurate disease classification, prognostic assessment, and guiding targeted treatment strategies.

The CD15 test is a diagnostic laboratory evaluation used in hematopathology to detect expression of the CD15 cell-surface carbohydrate antigen (3-fucosyl-N-acetyllactosamine). Expressed prominently on mature neutrophils, eosinophils, and monocytes, CD15 serves as an important marker in immunophenotyping.
Conducted via immunohistochemistry or flow cytometry on blood, bone marrow, or tissue biopsies, this test is critical for diagnosing Classical Hodgkin Lymphoma, where CD15 is typically positive on characteristic Reed-Sternberg cells. It also aids in identifying granulocytic differentiation in Acute Myeloid Leukemia (AML). Evaluating CD15 expression assists clinicians in accurate cancer subtyping, staging, and determining optimal targeted therapies.

The CD16/CD56 test is a specialized diagnostic evaluation in immunopathology used to identify and quantify Natural Killer (NK) cells. CD56 serves as a primary surface marker for NK cells and a subset of T-cells, while CD16 acts as an Fc receptor involved in antibody-dependent cellular cytotoxicity.
Performed via flow cytometry on peripheral blood, this dual-marker panel assesses overall NK cell population, maturity, and function. It is essential for evaluating primary immunodeficiencies, investigating recurrent pregnancy loss, and diagnosing NK-cell or T/NK-cell lymphoproliferative disorders. Detecting CD16/CD56 expression provides critical data for staging hematologic malignancies and monitoring immune system status.